Better Health for All

Evaxion's core business is dedicated to developing revolutionary health benefits, with 100% of its pipeline focused on cancer and infectious disease vaccines.

Its EVX-01 personalized cancer vaccine has shown a 69% overall response rate and tumor reduction in 15 out of 16 patients in trials, with 80% of vaccine targets triggering a tumor-specific immune response. The company is also researching a polio vaccine with the goal of eradication and developing a vaccine for Group A Streptococcus, which addresses a significant global health burden. No revenue is derived from harmful products. Clinical trials for EVX-01 and EVX-02 have reported only grade 1-2 adverse drug reactions, and EVX-03 GLP toxicology showed no safety concerns, indicating an outstanding safety record. The company collaborates with Afrigen to develop the EVX-B2 vaccine for low- and middle-income countries, demonstrating efforts to reach vulnerable populations. Evaxion clearly identifies forward-looking statements and outlines risks in its presentations, showing excellent risk transparency. The company's R&D expenses were $10.5 million in 2024, with plans to maintain similar spending in 2025, and it received grant funding from the Gates Foundation for polio vaccine research, indicating over 25% of its revenue is invested in health innovation. The collaboration with Afrigen also serves as a health equity program. The company's focus on vaccine development for infectious diseases, including polio and GAS, demonstrates a strong commitment to preventative health measures. Evaxion's research into a polio vaccine addresses a potential global resurgence, showing leadership in global health crisis response. The phase 2 trial for EVX-01 is investigating the vaccine in combination with Merck's KEYTRUDA®, with each patient receiving a unique vaccine tailored to their individual biology, reflecting strong ethical frameworks in clinical trials.

Fair Money & Economic Opportunity

Evaxion A/S is a clinical-stage biotechnology company focused on developing immunotherapies.

The provided articles detail its financial performance, R&D activities, clinical trials, and executive changes. None of the articles contain specific, concrete data points or explicit statements regarding the company's involvement in lending, deposit services, or other financial activities relevant to the 'Fair Money & Economic Opportunity' value. Therefore, all KPIs under this value must be omitted due to a lack of direct evidence in the provided articles.

Honest & Fair Business

Evaxion A/S has a Whistleblower Policy, adopted by the Board on June 12, 2025, which allows for voluntary and anonymous reporting of serious violations through an independent external email and other external systems.

The policy explicitly protects whistleblowers from retaliation and promises feedback within three months of report confirmation. The company's financial statements for the period ending December 31, 2024, do not reflect the correction of an error to previously issued financial statements that required a recovery analysis of incentive-based compensation. Evaxion also has an Anti-Corruption, Anti-Bribery, and OFAC Policy Statement and Compliance Guide, adopted on June 12, 2025, which mandates worldwide compliance, requires risk-based due diligence for third parties, and sets a limit of $200 for gifts to government officials in a twelve-month period without prior written approval.

Kind to Animals

Evaxion utilizes AI-based in-silico predictions for screening and identifying vaccine candidates

, but these are subsequently tested and validated in live animal models , indicating that non-animal assays cover early-stage screens but are not used for complex endpoints. The company's animal testing policy prohibits discretionary testing, but legal mandates still override alternatives, as evidenced by their use of animal testing for medical analysis and clinical research. All animal experiments are conducted in accordance with Danish law and approved by the Danish Animal Experiments Inspectorate and the animal welfare committee at the University of Copenhagen. Evaxion operates a modern research facility for in vivo models, emphasizing compliance with stringent Danish and European ethical standards, and has an animal welfare organ to discuss ethics and replacement options. They commit to humane and responsible research, providing enrichment and minimizing suffering, including daily clinical monitoring, anesthesia, and defined euthanasia criteria. In 2025, 106 mice were used in a *Pseudomonas aeruginosa* lung infection study , and in 2024, three separate studies were conducted in large, non-rodent animals for the EVX-B1 vaccine candidate.

Zero Waste & Sustainable Products

The provided article focuses on the financing of a drug discovery platform and pipeline for vaccines and treatments, which is primarily a research and development project.

It does not contain any specific data or information related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education for Evaxion A/S.